- Home
- KOD vs OPY Comparison
KOD vs OPY Comparison
Compare KOD & OPY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | OPY |
|---|---|---|
| Founded | 2009 | 1881 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 795.5M | 715.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOD | OPY |
|---|---|---|
| Price | $24.09 | $73.44 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.67 | N/A |
| AVG Volume (30 Days) | ★ 720.6K | 38.0K |
| Earning Date | 11-13-2025 | 01-30-2026 |
| Dividend Yield | N/A | ★ 0.99% |
| EPS Growth | N/A | ★ 16.17 |
| EPS | N/A | ★ 7.46 |
| Revenue | N/A | ★ $1,453,063,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.80 |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $1.92 | $49.26 |
| 52 Week High | $26.21 | $79.99 |
Technical Indicators
Market Signals| Indicator | KOD | OPY |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 68.73 |
| Support Level | $21.24 | $66.73 |
| Resistance Level | $24.97 | $77.10 |
| Average True Range (ATR) | 1.70 | 2.25 |
| MACD | -0.16 | 0.72 |
| Stochastic Oscillator | 62.58 | 69.31 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.